The Effect of EDP on Diaphragmatic Function and Neural Respiratory Drive in Patient With AECOPD
Launched by ZHUJIANG HOSPITAL · Mar 13, 2017
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Patients with AECOPD will participate in a rehabilitation program for one week. Participants in the proposed study will be randomly divided into two intervention groups:controlgroup and EDP therapy group. Before using EDP,the investigators will measure the relevant parameters of lung volume , diaphragm electromyogram, diaphragm activity and other basline index. Then EDP will be applied to investigate the effects of EDP on the above mentioned respiratory mechanics parameters.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with pulmonary function test of forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) \< 70% after inhalation of bronchial dilation agent.
- • Patients in a clinically acute exacebation state.
- Exclusion Criteria:
- • Patients were excluded if they had evidence of pneumothorax or mediastinal emphysema and pacemaker installed.
- • Patients with acute cardiovascular event and severe cor pulmonale.
- • Patients with poor compliance.
- • An Other causes of diaphragmatic dysfunction.
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Xin Chen, Doctor
Principal Investigator
Zhujiang Hospital,Southern Medical Unversity
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials